Aldeyra Therapeutics, Inc. · NASDAQ:ALDX

Aldeyra Therapeutics — Technical Presentation (February 2026)

12 slides from Aldeyra Therapeutics's technical presentation, Feb 27, 2026

1. Slide 1: Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution in Dry Eye Disease

   Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution in Patients With Title of Presentation, Title Case Dry Eye Disease: Results From a Dry Eye Chamber Trial Justin Schweitzer, OD1, Jaclyn Garlich, OD2, Patricia Couroux, MD3, Desiree Owen, OD4, Ashley Nguyen, PharmD4, Todd Brady, MD, PhD5 1Va

2. Slide 2: Acknowledgments, funding and disclosures

   Aldeyra Therapeutics, AbbVie Inc., and the authors thank the participants, study sites, and investigators who participated in this clinical trial. Aldeyra Therapeutics funded this trial and participated in the trial design, research, data collection, analysis, interpretation of data, and review and

3. Slide 3: Introduction

   Introduction Objective: To evaluate the efficacy and safety of reproxalap compared with a vehicle ophthalmic solution in improving ocular discomfort in patients with dry eye disease (DED) DED is a common ocular condition that is characterized in part by ocular discomfort • Many current therapeutic o

4. Slide 4: Methods

   Methods Study Design: Randomized, double-masked, vehicle-controlled, parallel group, Phase 3 clinical trial that was conducted in a dry eye chamber and included 4 visits Visit 1: Screening Visit 2: Vehicle Chamber Visit Medical screening and administration of All patients received vehicle ~ 5 minute

5. Slide 5: Figure 1. Patient Disposition

   Figure 1. Patient Disposition Randomized N = 132 Reproxalap Vehicle (N = 66) (N = 66) Discontinued (n = 1) Lost to follow up, n = 1 Completed Completed (n = 65) (n = 66)

6. Slide 6: Baseline characteristics were similar for both groups

   Baseline characteristics were similar for both groups Table 1. Baseline Characteristics Reproxalap Vehicle Outcome N = 66 N = 66 Age, mean (SD) 49.6 (11.9) 46.5 (11.5) Age ≥ 65, n (%) 6 (9.1) 5 (7.6) Female, n (%) 53 (80.3) 41 (62.1) Ethnicity, n (%) Hispanic or Latino 10 (15.2) 16 (24.2) Not Hispan

7. Slide 7: Reproxalap-treated patients experienced significantly less ocular discomfort

   Reproxalap-treated patients experienced significantly less ocular discomfort Table 2. Primary Efficacy Analysis of Ocular Discomfort Symptom Score (ITT Population): Treatment Chamber vs Vehicle Chamber for Time Points of ≥ 80 Minutes After Chamber Entry Reproxalap Vehicle Outcome N = 66 N = 66 Mean

8. Slide 8: Ocular discomfort remained lower in reproxalap-treated patients for the entirety of the chamber

   Ocular discomfort remained lower in reproxalap-treated patients for the entirety of the chamber Figure 2. Mean Change from Baseline for Ocular Discomfort Score at Each Timepoint in the Randomized Treatment Dry Eye Chamber (Treatment Chamber) (ITT Population) • Change from baseline in ocular discomfo

9. Slide 9: Ocular discomfort scores were lower for a greater proportion of reproxalap-treated patients

   Ocular discomfort scores were lower for a greater proportion of reproxalap-treated patients Figure 3. Distribution Function of Time-Matched Change from Baseline in Ocular Discomfort Dry Eye Chamber Score (Treatment Chamber- Vehicle Chamber) Averaged Across Eyes and Primary Endpoint Contrast Timepoin

10. Slide 10: Most ocular TEAEs were mild or moderate for reproxalap-treated patients

    Most ocular TEAEs were mild or moderate for reproxalap-treated patients Table 3. All Treatment and Ocular Treatment-Emergent Adverse Events (Safety Population) • 60 (90.9%) of patients in the reproxalap group experienced 299 Reproxalap Vehicle TEAEs compared with 20 (15.2%) of patients in the vehicl

11. Slide 11: Limitations

    Limitations • Interpretation of this study is limited by several factors, including: • Single-center design • Small number of patients included • Long-term effects not assessed

12. Slide 12: Conclusions

    Conclusions Patient-reported ocular discomfort scores from Vehicle Chamber to Treatment Chamber for 80 to 100 minutes after dry eye chamber entry were significantly lower in reproxalap-treated patients compared with vehicle-treated patients The primary endpoint of ocular discomfort symptom score was

Aldeyra Therapeutics — Technical Presentation (February 2026) on 6ix